Our medicines block the action of KMO - a key enzyme at the interface of inflammation, immunity and metabolism.
Our vision is to revolutionise the health and well-being of patients where uncontrolled inflammation is causing suffering, for example critical illness and in chronic inflammatory conditions, and in cancers where inflammation is preventing the immune system from fighting back.
KMO plays a major role in the regulation of systemic inflammation and in the pathology of conditions where there is a pressing need for new medicines
Kynos Therapeutics Ltd.
Enterprise Hub 2.14
10 Max Born Crescent
Edinburgh EH9 3BF